Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

Tuvusertib (Synonyms: M1774, ATR inhibitor 1)

Catalog No. T10406 Copy Product Info
Purity: 99.66%
🥰Excellent
Tuvusertib (M1774) is an orally available ataxia telangiectasia and Rad3-related (ATR) kinase inhibitor (Ki< 1 µΜ) with selective and potentially antitumor activity.Tuvusertib selectively inhibits ATR activity and blocks downstream phosphorylation of serine/threonine protein kinase checkpoint kinase 1 (CHK1), thereby inhibits DNA damage checkpoint activation, disrupting DNA damage repair and inducing apoptosis in tumor cells.

Tuvusertib

Copy Product Info
🥰Excellent
Catalog No. T10406
Synonyms M1774, ATR inhibitor 1

Tuvusertib (M1774) is an orally available ataxia telangiectasia and Rad3-related (ATR) kinase inhibitor (Ki< 1 µΜ) with selective and potentially antitumor activity.Tuvusertib selectively inhibits ATR activity and blocks downstream phosphorylation of serine/threonine protein kinase checkpoint kinase 1 (CHK1), thereby inhibits DNA damage checkpoint activation, disrupting DNA damage repair and inducing apoptosis in tumor cells.

Tuvusertib
Cas No. 1613200-51-3
TargetMol | Customer service
Customer service consultation
Pack SizePriceUSA StockGlobal StockQuantity
1 mg$56-In Stock
5 mg$133-In Stock
10 mg$208-In Stock
25 mg$403-In Stock
50 mg$562-In Stock
100 mg$797-In Stock
1 mL x 10 mM (in DMSO)$153-In Stock
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Questions
TargetMol
View More

Batch Information

Select Batch
Purity:99.66%
Appearance:Solid
Color:Yellow
Contact us for more batch information

Resource Download

Product Introduction

Bioactivity
Description
Tuvusertib (M1774) is an orally available ataxia telangiectasia and Rad3-related (ATR) kinase inhibitor (Ki< 1 µΜ) with selective and potentially antitumor activity.Tuvusertib selectively inhibits ATR activity and blocks downstream phosphorylation of serine/threonine protein kinase checkpoint kinase 1 (CHK1), thereby inhibits DNA damage checkpoint activation, disrupting DNA damage repair and inducing apoptosis in tumor cells.
SynonymsM1774, ATR inhibitor 1
Chemical Properties
Molecular Weight370.32
FormulaC16H12F2N8O
Cas No.1613200-51-3
SmilesCn1cncc1-c1c(F)cncc1NC(=O)c1c(N)nn2cc(F)cnc12
Relative Density.1.68 g/cm3 (Predicted)
Storage & Solubility Information
Storagestore at low temperature,keep away from direct sunlight,keep away from moisture | Shipping with blue ice/Shipping at ambient temperature.
Solubility Information
DMSO: 6.67 mg/mL (18.01 mM), Sonication is recommended.
Solution Preparation Table
DMSO
1mg5mg10mg50mg
1 mM2.7004 mL13.5018 mL27.0037 mL135.0184 mL
5 mM0.5401 mL2.7004 mL5.4007 mL27.0037 mL
10 mM0.2700 mL1.3502 mL2.7004 mL13.5018 mL
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
TargetMol | Animal experiments For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent 10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.
Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSOTargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSOTargetMol | reagent stock solution to 400 μL PEG300TargetMol | reagent and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH2OTargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy Tuvusertib | purchase Tuvusertib | Tuvusertib cost | order Tuvusertib | Tuvusertib chemical structure | Tuvusertib formula | Tuvusertib molecular weight